|
Shares in Eco Animal Health Group PLC rose on Monday after the European Medicines Agency adopted a positive opinion on authorising its poultry vaccine. The London-based animal health company called this a ‘key milestone’ in its EU commercialisation plans. Its shares rose 8.0% to 87.50 pence on Monday morning in London. Ecovaxxin MS is a vaccine against mycoplasma synoviae, a disease-causing bacteria which affects birds’ joints, bones and respiratory systems. Eco Animal said it helps reduce air-sac and foot-pad lesions in chickens from four weeks of age. A formal ‘positive opinion’ from the EMA’s Committee for Medicinal Products for Veterinary Use means the regulator is likely to grant EU marketing authorisation for the drug. Eco Animal expects formal approval in the first quarter of 2026, and is targeting EU commercialisation in the second half. It is planning applications to regulators in other regions over the next 12 months, for Ecovaxxin MS and other products in the pipeline. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
